Metrion Biosciences and Grünenthal Group extended their ion channel drug discovery collaboration

Metrion Biosciences, a UK-based ion channel CRO, announced the extension of its long-standing ion channel drug discovery research agreement with the Grünenthal Group, a global leader in pain research.

Metrion will be providing dedicated ion channel expertise in the form of FTE based services, including electrophysiology screening of Grünenthal’s medicinal chemistry compounds.